methylphenidate has been researched along with Pain, Intractable in 4 studies
Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.
methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.
methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.
Pain, Intractable: Persistent pain that is refractory to some or all forms of treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Delirium is frequently observed in terminally ill cancer patients, but complete remission is often difficult to achieve." | 5.31 | Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. ( Chihara, S; Inoue, S; Morita, T; Otani, H; Tsunoda, J, 2000) |
| "Delirium is frequently observed in terminally ill cancer patients, but complete remission is often difficult to achieve." | 1.31 | Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate. ( Chihara, S; Inoue, S; Morita, T; Otani, H; Tsunoda, J, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (50.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Okon, T | 1 |
| Wilwerding, MB | 1 |
| Loprinzi, CL | 1 |
| Mailliard, JA | 1 |
| O'Fallon, JR | 1 |
| Miser, AW | 1 |
| van Haelst, C | 1 |
| Barton, DL | 1 |
| Foley, JF | 1 |
| Athmann, LM | 1 |
| Yee, JD | 1 |
| Berde, CB | 1 |
| Morita, T | 1 |
| Otani, H | 1 |
| Tsunoda, J | 1 |
| Inoue, S | 1 |
| Chihara, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Randomized Study Evaluating the Antiasthenic Effect of Methylphenidate (Ritalin) in Palliative Care in Cancer Patients[NCT00273741] | Phase 3 | 39 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to difficulty of recrutement) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 0 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 0 |
| Ketamine 1.5 mg/kg/Dose | 0 |
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
| Intervention | ng/mL (Mean) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 37.5 |
| Ketamine 0.5 mg/kg/Dose | 135 |
| Ketamine 1 mg/kg/Dose | 250 |
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 3 |
| Ketamine 1 mg/kg/Dose | 3 |
| Ketamine 1.5 mg/kg/Dose | 1 |
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 2 |
| Ketamine 1.5 mg/kg/Dose | 0 |
1 review available for methylphenidate and Pain, Intractable
| Article | Year |
|---|---|
Ketamine: an introduction for the pain and palliative medicine physician.
Topics: Adult; Amines; Analgesics; Analgesics, Opioid; Central Nervous System; Cryoglobulinemia; Cyclohexane | 2007 |
1 trial available for methylphenidate and Pain, Intractable
| Article | Year |
|---|---|
A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Methylphenid | 1995 |
2 other studies available for methylphenidate and Pain, Intractable
| Article | Year |
|---|---|
Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer.
Topics: Adjuvants, Pharmaceutic; Adolescent; Adult; Analgesics, Opioid; Dextroamphetamine; Female; Humans; M | 1994 |
Successful palliation of hypoactive delirium due to multi-organ failure by oral methylphenidate.
Topics: Central Nervous System Stimulants; Delirium; Female; Humans; Methylphenidate; Middle Aged; Multiple | 2000 |